Y-mAbs Therapeutics, Inc. (YMAB)
YMAB Stock Price Chart
Explore Y-mAbs Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze YMAB price movements and trends.
YMAB Company Profile
Discover essential business fundamentals and corporate details for Y-mAbs Therapeutics, Inc. (YMAB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
21 Sept 2018
Employees
104.00
Website
https://www.ymabs.comCEO
Michael Rossi
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma. The company is also developing DANYELZA that is in Phase II clinical studies for the treatment of patients with first-line neuroblastoma, third-line neuroblastoma, and in relapsed osteosarcoma; GD2-GD3 vaccine that is in Phase II clinical trial for the treatment of Stage 4 high-risk neuroblastoma; and Omburtamab, a murine monoclonal antibody that is in clinical trials for the treatment of central nervous system/ leptomeningeal metastases from neuroblastoma, desmoplastic small round cell tumor, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors. In addition, it is developing Nivatrotamab for the treatment of small cell lung cancer, as well as is in Phase I/II trial for the treatment of refractory GD2 positive adult and pediatric solid tumors; and Lu-omburtamab-DTPA that is in Phase I clinical development for the treatment of medulloblastoma and B7-H3 positive leptomeningeal metastases from solid tumors. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.
YMAB Financial Timeline
Browse a chronological timeline of Y-mAbs Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 2 Mar 2026
Upcoming earnings on 14 Nov 2025
EPS estimate is -$0.23.
Earnings released on 8 Aug 2025
EPS came in at -$0.07 surpassing the estimated -$0.27 by +74.07%, while revenue for the quarter reached $19.53M , missing expectations by -7.11%.
Earnings released on 13 May 2025
EPS came in at -$0.12 surpassing the estimated -$0.22 by +45.45%, while revenue for the quarter reached $20.90M , beating expectations by +12.31%.
Earnings released on 4 Mar 2025
EPS came in at -$0.15 falling short of the estimated -$0.13 by -15.38%, while revenue for the quarter reached $26.50M , beating expectations by +17.84%.
Earnings released on 8 Nov 2024
EPS came in at -$0.16 falling short of the estimated -$0.14 by -14.29%, while revenue for the quarter reached $18.46M , missing expectations by -31.29%.
Earnings released on 12 Aug 2024
EPS came in at -$0.21 falling short of the estimated -$0.13 by -61.54%, while revenue for the quarter reached $22.80M , missing expectations by -0.96%.
Earnings released on 7 May 2024
EPS came in at -$0.15 falling short of the estimated -$0.12 by -25.00%, while revenue for the quarter reached $19.93M , missing expectations by -10.30%.
Earnings released on 29 Feb 2024
EPS came in at -$0.02 surpassing the estimated -$0.19 by +89.47%, while revenue for the quarter reached $23.36M , beating expectations by +0.44%.
Earnings released on 13 Nov 2023
EPS came in at -$0.18 falling short of the estimated -$0.16 by -12.50%, while revenue for the quarter reached $20.45M , missing expectations by -2.27%.
Earnings released on 10 Aug 2023
EPS came in at -$0.14 surpassing the estimated -$0.24 by +41.67%, while revenue for the quarter reached $20.75M , beating expectations by +1.97%.
Earnings released on 8 May 2023
EPS came in at -$0.15 surpassing the estimated -$0.31 by +51.61%, while revenue for the quarter reached $20.25M , beating expectations by +28.99%.
Earnings released on 30 Mar 2023
EPS came in at $0.03 surpassing the estimated -$0.46 by +106.52%, while revenue for the quarter reached $31.45M , beating expectations by +56.76%.
Earnings released on 7 Nov 2022
EPS came in at -$0.63 surpassing the estimated -$0.75 by +16.00%, while revenue for the quarter reached $12.54M , beating expectations by +4.35%.
Earnings released on 8 Aug 2022
EPS came in at -$0.94 falling short of the estimated -$0.68 by -38.24%, while revenue for the quarter reached $10.80M , missing expectations by -3.83%.
Earnings released on 9 May 2022
EPS came in at -$0.64 surpassing the estimated -$0.71 by +9.86%, while revenue for the quarter reached $10.49M , missing expectations by -3.80%.
Earnings released on 24 Feb 2022
EPS came in at -$0.85 falling short of the estimated -$0.71 by -19.72%, while revenue for the quarter reached $9.60M , missing expectations by -10.92%.
Earnings released on 4 Nov 2021
EPS came in at -$0.66 falling short of the estimated -$0.60 by -10.00%, while revenue for the quarter reached $8.97M , missing expectations by -17.68%.
Earnings released on 5 Aug 2021
EPS came in at -$0.53 surpassing the estimated -$0.68 by +22.06%, while revenue for the quarter reached $10.95M , meeting expectations.
Earnings released on 6 May 2021
EPS came in at $0.75 surpassing the estimated $0.61 by +22.95%, while revenue for the quarter reached $5.38M , missing expectations by -42.94%.
Earnings released on 25 Feb 2021
EPS came in at -$0.49 surpassing the estimated -$0.85 by +42.35%, while revenue for the quarter reached $20.75M , missing expectations by -5.56%.
Earnings released on 5 Nov 2020
EPS came in at -$0.82 falling short of the estimated -$0.80 by -2.50%.
YMAB Stock Performance
Access detailed YMAB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.